Yetzabel Lamar Morales
Internal Medicine · Tampa, FLNPI 1487001202
Payments from drug & device makers
Across 140 payments — averaging $27.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Novo Nordisk$605
- Bayer$351
- Boehringer Ingelheim$290
- Amgen$221
- Kowa Pharmaceuticals America, Inc.$164
- plus $1K from 17 others
What the payments were for
- Food & beverage$3,83499%
- Education$281%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 31 | $1,166 |
| Novo Nordisk | 23 | $605 |
| Bayer | 13 | $351 |
| Boehringer Ingelheim | 12 | $290 |
| Amgen | 13 | $221 |
| Kowa Pharmaceuticals America, Inc. | 7 | $164 |
| Intuitive Surgical | 1 | $124 |
| Lilly USA, LLC | 6 | $117 |
| Pfizer | 6 | $114 |
| Organogenesis Inc. | 1 | $111 |
| Johnson & Johnson | 2 | $101 |
| Exact Sciences | 5 | $83 |
| AbbVie | 4 | $71 |
| Abbott | 3 | $62 |
| Hologic Sales And Service, LLC | 2 | $51 |
| Ultragenyx Pharmaceutical Inc. | 2 | $50 |
| Kyowa Kirin, Inc. | 2 | $38 |
| Phadia US Inc. | 2 | $35 |
| Gilead | 1 | $29 |
| Corcept Therapeutics | 1 | $25 |
| Astellas Pharma US Inc | 1 | $20 |
| Lucid Diagnostics Inc. | 1 | $18 |
| Inari Medical, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,862 in reported general payments places this provider in the 85th percentile of 8,530 internal medicine providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 43 | $68,292 |
| TrulicityDulaglutide | 22 | $38,513 |
| MounjaroTirzepatide | 21 | $22,050 |
| XareltoRivaroxaban | 13 | $4,224 |
| Celecoxib | 43 | $2,337 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 49 | $1,060 |
| Atorvastatin Calcium | 77 | $896 |
| Levothyroxine Sodium | 71 | $737 |
| Diclofenac Sodium | 45 | $721 |
| Ketoconazole | 47 | $651 |
| Azelastine Hcl | 11 | $577 |
| Rosuvastatin Calcium | 52 | $554 |
| Montelukast Sodium | 37 | $519 |
| Losartan Potassium | 46 | $452 |
| Quetiapine Fumarate | 16 | $445 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $605 | $68,29243 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $117 | $60,56343 claims |
| Johnson & JohnsonXarelto | $101 | $4,22413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Tampa
- Jhanelle GrayTampa$20.8M
- Sady AlpizarTampa$13.5M
- Karon LociceroTampa$6.6M
- Yaneicy Gonzalez RojasCoral Gables$93.5M
- Juan Carlos RondonHollywood$66.8M
- Jaynier MoyaPembroke Pines$45.4M
- Mark KutnerMiami$35.7M
- Gilberto JimenezHialeah$35.6M
- Mira BaronWest Palm Beach$29.6M
- William SanchezHialeah$28.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.